Recent News

• 12.08.2025 - Subgroup Analysis of Japanese Patients in the Phase II Study of Taletrectinib in Patients with ROS1+ NSCLC: The Global TRUST-II Study
• 12.03.2025 - Phase 2, multicenter, randomized clinical study to evaluate the efficacy and safety of safusidenib in patients with high-grade isocitrate dehydrogenase 1 (IDH1)-mutant glioma
• 11.18.2025 - Phase II Study of Safusidenib Erbumine in Patients with Chemotherapy- and Radiotherapy-Naïve Isocitrate Dehydrogenase 1-Mutated WHO Grade 2 Gliomas

Recent Filings

• 12.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.01.2025 - 144 Report of proposed sale of securities
• 11.26.2025 - 144 Report of proposed sale of securities
• 11.26.2025 - 8-K Current report
• 11.26.2025 - EX-99.1 EX-99.1
• 11.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.25.2025 - 144 Report of proposed sale of securities
• 11.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.21.2025 - 4 Statement of changes in beneficial ownership of securities